| …that changes
the way we do things. All it takes is the ability to see things
in extraordinary ways. That’s the kind of innovative thinking
that drives Targepeutics, a biopharmaceutical company with
remarkable breakthrough technologies for the treatment, imaging
and diagnosis of cancer and other dreaded diseases. |
Three
Unique Breakthrough Technologies Comprise Our Pharmaceutical Platform:
I Targeting Using Genetically Engineered Interleukin
13 (IL-13)
Targeting molecules are combined with a variety of dynamic agents
for cancer diagnosis, imaging and treatment, using the characteristics
unique to cancer cells to develop tumor management strategies.
II Immunotherapy
Interleukin 13 antagonists and prototype vaccines for the treatment
of cancer and asthma, modulating the body’s immune system
to better combat tumors and control consequences of allergic reaction
in asthma.
III Anti-Angiogenesis
Development of compounds to control several solid tumors in their
advanced stages, inhibiting the growth and ability of tumors to
create new blood vessels, making the tumors more susceptible to
conventional treatments. |
Research
and Development Program
Dr. Waldemar Debinski and his associates have established a
biopharmaceutical research and development program that:
• Carefully proves and substantiates scientific validity
of its technology
• Maintains compounds in the lab until their clinical prospects
are apparent
• Sets clear clinical trial entry and progression milestones
for its relationship with the investment community
Vision and Science Lead to
Execution
The biopharmaceutical development program of Targepeutics
has a set of platform technologies and compounds that are comparable
to those of more mature biopharmaceutical companies. In the next
several years, Targepeutics plans to put 19 cancer treatment,
imaging and diagnostic compounds into clinical trials. The Company also
plans to develop cancer diagnostic test kits and sublicense its
asthma treatment technology in this same time frame.
Dr. Debinski’s ongoing research continues to uncover new
and advanced opportunities to treat cancer and other diseases.
Targepeutics is excited to have exclusive rights to this
technology and looks forward to fully developing its commercial
potential. |
Back to 
|